|
Market Cap (2-Jul) $12,281,100 (923rd) |
Close (30-Jun) $0.125 |
Volume (30-Jun) 0 |
Shortsold (17-Apr) 8,415 (0.00%) (600th) |
|
52w High $0.058 |
52w Low $0.021 |
P/E - |
EPS -0.004 |
EMD released this announcement to the ASX on 30 January 2023, 9:37. The announcement is marked as price sensitive, and is 4 page(s) in length and 0.94MB in size.
You can view all announcements from EMD and see how they appear on a price chart on the announcements page.
At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).
| Other Recent Announcements from EMD | |
|---|---|
| Trading Halt | 29 June 2023, 9:33 |
| Emyria Receives Ethics Approval for MDMA-assisted Therapy | 8 June 2023, 9:10 |
| Section 708A(5)(e) Notice | 10 May 2023, 18:37 |
| First dosing commenced for pivotal EMD-RX5 Phase 3 trial | 30 January 2023, 9:37 |
| Results of Meeting | 25 January 2023, 18:04 |
| Emyria receives $2.1M R&D tax incentive refund | 12 January 2023, 9:41 |
| Biotech Showcase San Francisco Presentation | 10 January 2023, 9:28 |
You must be logged in to post a reply.
Emyria 